Prokidney Corp (PROK)

$3.62

-0.08

(-2.16%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Prokidney Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 121.5%

Performance

  • $3.57
    $3.74
    $3.62
    downward going graph

    1.38%

    Downside

    Day's Volatility :4.55%

    Upside

    3.21%

    downward going graph
  • $1.12
    $13.51
    $3.62
    downward going graph

    69.06%

    Downside

    52 Weeks Volatility :91.71%

    Upside

    73.21%

    downward going graph

Returns

PeriodProkidney CorpIndex (Russel 2000)
3 Months
146.67%
0.0%
6 Months
106.7%
0.0%
1 Year
-63.04%
0.0%
3 Years
-62.89%
-20.1%

Highlights

Market Capitalization
1.8B
Book Value
- $17.79
Earnings Per Share (EPS)
-0.57
Wall Street Target Price
6.17
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.34%
Return On Equity TTM
-31.72%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-146.6M
Diluted Eps TTM
-0.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.24
EPS Estimate Next Year
-0.68
EPS Estimate Current Quarter
-0.18
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Prokidney Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 70.44%

Current $3.62
Target $6.17

Technicals Summary

Sell

Neutral

Buy

Prokidney Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prokidney Corp
Prokidney Corp
36.03%
106.7%
-63.04%
-62.89%
-62.89%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prokidney Corp
Prokidney Corp
NA
NA
NA
-1.24
-0.32
-0.21
NA
-17.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prokidney Corp
Prokidney Corp
Buy
$1.8B
-62.89%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    17.52%

  • Suvretta Capital Management, LLC

    6.05%

  • BlackRock Inc

    4.49%

  • Bleichroeder LP

    3.13%

  • Vanguard Group Inc

    2.84%

  • Brown University

    1.56%

Company Information

prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.

Organization
Prokidney Corp
Employees
163
CEO
Dr. Timothy A. Bertram D.V.M., Ph.D.
Industry
Financial

Discover More

FAQs